What question did this study set out to answer?

To evaluate the effect of varying preoperative radiation doses combined with pembrolizumab on tumor cellular infiltration in HR+/HER2- breast cancer.

February 19, 2026Clinical Cancer Research

Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

View Full Paper

Ask AI

Bookmark

To evaluate the effect of varying preoperative radiation doses combined with pembrolizumab on tumor cellular infiltration in HR+/HER2- breast cancer.
Randomized trial with patients receiving no, low, or high doses of preoperative radiation (0Gy, 9Gy, 24Gy) and pembrolizumab.
Patients had HR+/HER2- breast cancer with node-positive disease and were stratified by tumor and node status.
Endpoints included tumor cellular infiltration (TCI) at 2 weeks and nodal pathologic complete response (ypN0) at definitive surgery.
Among 51 enrolled patients, significant improvement in TCI was observed in the 24Gy group compared to baseline (p=0.027).
The overall nodal pathologic complete response rate (ypN0) was 29%; 24% for 0Gy, 29% for 9Gy, and 33% for 24Gy.
pCR/RCB 0-1 rates were 18% overall and varied by treatment arm: 6%/18% (0Gy), 29%/29% (9Gy), and 19%/33% (24Gy).

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial examines preoperative radiation doses combined with pembrolizumab in HER2-negative breast cancer, indicating potential benefits with high-dose radiation.

Cite This Study

Gupta et al. (2026) studied this question.

synapsesocial.com/papers/6996a887ecb39a600b3ef563 https://doi.org/10.1158/1557-3265.sabcs25-gs2-05

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial examines preoperative radiation doses combined with pembrolizumab in HER2-negative breast cancer, indicating potential benefits with high-dose radiation.

Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Abstract GS2-05: Primary Results from the HR+/HER2- Cohort of TBCRC-053 (P-RAD): A Randomized Trial of No, Low, or High Dose Preoperative RADiation with Pembrolizumab and Chemotherapy in Node-Positive, HER2-Negative Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider